# US 2016/0354461 A1 · Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354461 A1
- Document ID: US20160354461A1
- Status: Published application
- Kind: A1
- Application number: 15/092,024
- Filed: 2016-04-06
- Published: 2016-12-08
- Earliest claimed: 2004-05-25
- Assignees: Oregon Health & Science University
- Applicants: Oregon Health & Science University
- Inventors: Louis J. Picker; Michael A. Jarvis; Jay A. Nelson
- Web page: https://patentgrep.com/patent/US20160354461A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/12: Viral antigens
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 16/089: {Cytomegalovirus}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/572: {cytotoxic response}
- C07K 2319/00: Fusion polypeptide
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16143: viral genome or elements thereof as genetic vector
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/15034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2830/003: tet inducible
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors.

## Claims

### Claim 1

A method for the treatment or prevention of HIV, the method comprising infecting a human subject in need thereof with at least one recombinant vaccine vector,
wherein the recombinant vaccine vector comprises a replicative human cytomegalovirus (HCMV) strain and at least one HIV antigen, and
wherein the recombinant vaccine vector expresses the HIV antigen long-term in the subject and invokes a persistent cellular immune response to the HIV antigen in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is an immunocompetent, HCMV-seropositive subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the HIV antigen of the recombinant vaccine vector is selected from the group consisting of: gag, pol, env, nef, rev, tat, vif, vpr, and vpu, or an epitope or antigenic portion thereof.

### Claim 4 (depends on 1)

The method of claim 1, further comprising serially re-infecting the subject with at least one additional recombinant vaccine vector,
wherein the additional recombinant vaccine vector comprises a replicative HCMV strain and at least one HIV antigen, and
wherein the additional recombinant vaccine vector expresses the HIV antigen long-term in the subject and invokes a persistent cellular immune response to the HIV antigen in the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the HIV antigen of the recombinant vaccine vector is different than the HIV antigen of the additional recombinant vaccine vector.

### Claim 6 (depends on 1)

The method of claim 1, wherein expression of the HIV antigen of the recombinant vaccine vector is driven by an HIV antigen-encoding nucleic acid sequence in operable association with a promoter selected from the group consisting of: a constitutive promoter, an immediate early cytomegalovirus (CMV) promoter, an early CMV promoter, and a late CMV promoter.

### Claim 7 (depends on 6)

The method of claim 6, wherein the promoter is selected from the group consisting of: an EF1-alpha promoter, a CMV major immediate early (MIE) promoter, a CMV pp65 promoter, and a CMV gH promoter.

### Claim at position 8

8-39. (canceled)

### Claim 40 (depends on 4)

The method of claim 4, wherein the at least one HIV antigen of the additional recombinant vaccine vector is selected from the group consisting of: gag, pol, env, nef, rev, tat, vif, vpr, and vpu, or an epitope or antigenic portion thereof.

### Claim 41 (depends on 1)

The method of claim 1, wherein the recombinant vaccine vector is a prophylactic vaccine vector for the prevention of HIV, and wherein the subject is an HIV-seronegative subject.

### Claim 42 (depends on 1)

The method of claim 1, wherein the recombinant vaccine vector is a therapeutic vaccine vector for the treatment of HIV, and wherein the subject is an HIV-seropositive subject.

### Claim 43 (depends on 1)

The method of claim 1, wherein the recombinant vaccine vector comprises a safety or suicide means.

### Claim 44 (depends on 1)

The method of claim 1, wherein the recombinant vaccine vector comprises an HIV antigen-encoding nucleic acid sequence inserted into a nonessential open reading frame (ORF) of the replicative HCMV strain.

### Claim 45

A method for the treatment or prevention of HIV, the method comprising administering a pharmaceutical composition to a human subject in need thereof,
wherein the pharmaceutical composition comprises at least one recombinant vaccine vector,
wherein the recombinant vaccine vector comprises a nucleic acid sequence encoding a replicative HCMV strain and at least one HIV antigen, and
wherein the recombinant vaccine vector expresses the HIV antigen long-term in the subject and invokes a persistent cellular immune response to the HIV antigen in the subject.

### Claim 46 (depends on 45)

The method of claim 45, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

### Claim 47 (depends on 45)

The method of claim 45, wherein the subject is an immunocompetent, HCMV-seropositive subject.

### Claim 48 (depends on 45)

The method of claim 45, wherein the HIV antigen of the recombinant vaccine vector is selected from the group consisting of: gag, pol, env, nef, rev, tat, vif, vpr, and vpu, or an epitope or antigenic portion thereof.

### Claim 49 (depends on 45)

The method of claim 45, wherein expression of the HIV antigen of the recombinant vaccine vector is driven by an HIV antigen-encoding sequence in operable association with a promoter selected from the group consisting of: a constitutive promoter, an immediate early CMV promoter, an early CMV promoter and a late CMV promoter.

### Claim 50 (depends on 49)

The method of claim 49, wherein the promoter is selected from the group consisting of: an EF1-alpha promoter, a CMV MIE promoter, a CMV pp65 promoter, and a CMV gH promoter.

### Claim 51 (depends on 45)

The method of claim 45, wherein the recombinant vaccine vector is a prophylactic vaccine vector for the prevention of HIV, and wherein the subject is an HIV-seronegative subject.

### Claim 52 (depends on 45)

The method of claim 45, wherein the recombinant vaccine vector is a therapeutic vaccine vector for the treatment of HIV, and wherein the subject is an HIV-seropositive subject.

### Claim 53 (depends on 45)

The method of claim 45, wherein the recombinant vaccine vector comprises a safety or suicide means.

### Claim 54 (depends on 45)

The method of claim 45, wherein the recombinant vaccine vector comprises an HIV antigen-encoding nucleic acid sequence inserted into a nonessential ORF of the replicative HCMV strain.

### Claim 55 (depends on 45)

The method of claim 45, wherein the replicative HCMV strain comprises a nucleotide sequence at least 90%, at least 95%, or at least 99% identical to a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 2 to 9.

### Claim 56 (depends on 45)

The method of claim 45, wherein the replicative HCMV strain comprises a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 2 to 9.

### Claim 57 (depends on 45)

The method of claim 45, wherein the HIV antigen comprises an amino acid sequence at least 90%, at least 95%, or at least 99% identical to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 18 to 26 and 28 to 36.

### Claim 58 (depends on 45)

The method of claim 45, wherein the HIV antigen comprises a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 18 to 26 and 28 to 36.

### Claim 59

A method for the treatment or prevention of HIV, the method comprising infecting an immunocompetent, HCMV-seropositive human subject in need thereof with at least one recombinant vaccine vector;
wherein the recombinant vaccine vector comprises a replicative HCMV strain and at least one HIV antigen selected from the group consisting of: gag, pol, env, nef, rev, tat, vif, vpr, and vpu, or an epitope or antigenic portion thereof;
wherein expression of the HIV antigen is driven by an HIV antigen-encoding nucleic acid sequence in operable association with a promoter selected from the group consisting of: a constitutive promoter, an immediate early CMV promoter, an early CMV promoter and a late CMV promoter;
wherein the HIV antigen-encoding nucleic acid sequence is inserted into a nonessential ORF of the replicative HCMV strain; and
wherein the recombinant vaccine vector expresses the HIV antigen long-term in the subject and invokes a persistent cellular immune response to the HIV antigen in the subject.

### Claim 60 (depends on 59)

The method of claim 59, wherein the promoter is selected from the group consisting of: an EF1-alpha promoter, a CMV MIE promoter, a CMV pp65 promoter, and a CMV gH promoter.

### Claim 61 (depends on 59)

The method of claim 59, further comprising serially re-infecting the subject with at least one additional recombinant vaccine vector,
wherein the additional recombinant vaccine vector comprises a replicative HCMV strain and at least one HIV antigen, and
wherein the additional recombinant vaccine vector expresses the HIV antigen long-term in the subject and invokes a persistent cellular immune response to the HIV antigen in the subject.

### Claim 62 (depends on 61)

The method of claim 61, wherein the at least one HIV antigen of the additional recombinant vaccine vector is selected from the group consisting of: gag, pol, env, nef, rev, tat, vif, vpr, and vpu, or an epitope or antigenic portion thereof.

### Claim 63 (depends on 59)

The method of claim 59, wherein the recombinant vaccine vector is a prophylactic vaccine vector for the prevention of HIV, and wherein the subject is an HIV-seronegative subject.

### Claim 64 (depends on 59)

The method of claim 59, wherein the recombinant vaccine vector is a therapeutic vaccine vector for the treatment of HIV, and wherein the subject is an HIV-seropositive subject.

### Claim 65 (depends on 59)

The method of claim 59, wherein the recombinant vaccine vector comprises a safety or suicide means.
